BIMINI leverages the innovative biotech “portfolio model”. Instead of focussing on a single technology or biological pathway, BIMINI leverages multiple technologies to offer synergistic approaches or target different disease areas for major unmet medical needs. We do this through dedicated portfolio program management, smart fundraising, investments, venture creation and R&D. In addition, we leverage sector specific key expertise to maximise portfolio value.
With this approach, we de-risk our portfolio, offer more flexibility and are able to make a larger impact on society.
THE PROBLEM – The underlying biological mechanism in both these cases is the interaction between the human growth hormone (GH)/insulin-like growth factor 1 (IGF-1) and the GH receptor (GHR). GH modulates cellular metabolism leading to cell growth, cell reproduction, and cell regeneration. GH also stimulates the production and secretion of insulin-like growth factor 1 (IGF-1) in many tissues. GH and IGF-1 both promote cell proliferation and suppress apoptosis.
As such, the current scientific consensus is that the GH/IGF-1 axis promotes early stages of cancer, growth of cancer stem cells, epithelial to mesenchymal transition and metastasis. GH is overexpressed in colon, prostate, breast, lung, and melanoma cells where it binds the GHR to signal explosive cellular growth in a paracrine/autocrine fashion. Numerous animals studies also indicate the involvement of GH/IGF-1 in tumour growth, making this axis an ideal target for the development of cancer therapeutic options.
OUR SOLUTION – BIMINI’s breakthrough discovery has the potential to, for the first time, effectively leverage the GH/IGF-1 axis for the development of novel cancer therapeutics. Our approach elegantly mimics nature, such as seen in Laron syndrome, by rendering the cell to become less sensitive to growth hormone. Our approach relies on a novel mechanism, thereby rendering the GH/IGF-1 axis dysfunctional.
At BIMINI, we aim to develop a drug discovery platform around the GH/IGF-1 axis to become a leading innovator in GHR-based therapeutics.
EVIDENCE – We have identified four proprietary small molecules (BM001-004) of which BM001 is our lead compound that is currently in the pre-clinical phase. Our lead compound has been demonstrated both in in vitro as well as in vivo, showing promising anti-cancer effects for different cancer types.
Moreover, the GH/IGF-1 axis has been implicated in a variety of other indications including metabolic disorders and ageing, opening up opportunities that are associated with strong socio-economic unmet needs.
We are always open to discuss potential collaborations to bring innovative oncology therapeutics closer to the patient. Please feel free to contact us.